{"product_id":"polypharmacology-in-drug-discovery-isbn-9780470590904","title":"Polypharmacology in Drug Discovery","description":"\u003cp\u003eAn essential outline of the main facets of polypharmacology in drug discovery research\u003c\/p\u003e \u003cp\u003eExtending drug discovery opportunities beyond the \"one drug, one target\" philosophy, a polypharmacological approach to the treatment of complex diseases is emerging as a hot topic in both industry and academic research. Polypharmacology in Drug Discovery presents an overview of the various facets of polypharmacology and how it can be applied as an innovative concept for developing medicines for treating bacterial infections, epilepsy, cancer, psychiatric disorders, and more. Filled with a collection of instructive case studies that reinforce the material and illuminate the subject, this practical guide:\u003c\/p\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003eCovers the two-sided nature of polypharmacology—its contribution to adverse drug reactions and its benefit in certain therapeutic drug classes\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eAddresses the important topic of polypharmacology in drug discovery, a subject that has not been thoroughly covered outside of scattered journal articles\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eOverviews state-of-the-art approaches and developments to help readers understand concepts and issues related to polypharmacology\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eFosters interdisciplinary drug discovery research by embracing computational, synthetic, in vitro and in vivo pharmacological and clinical aspects of polypharmacology\u003c\/p\u003e \u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eA clear road map for helping readers successfully navigate around the problems involved with promiscuous ligands and targets, Polypharmacology in Drug Discovery provides real examples, in-depth explanations and discussions, and detailed reviews and opinions to spark inspiration for new drug discovery projects.\u003c\/p\u003e  \u003cb\u003eList of contributors.\u003c\/b\u003e  \u003cp\u003e\u003cb\u003ePreface.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIntroduction: the case for polypharmacology\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAndrew L. Hopkins\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart A: Polypharmacology – a safety concern in drug discovery.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 The relevance of off-target polypharmacology\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eBruce D. Car\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Screening for safety-relevant off-target activities\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eLaszlo Urban, Steven Whitebread, Jacques Hamon, Dmitri Mikhailov and Kamal Azzaoui\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction.\u003c\/p\u003e \u003cp\u003e2.2 General aspects.\u003c\/p\u003e \u003cp\u003e2.3 Selection of off-targets.\u003c\/p\u003e \u003cp\u003e2.4 In silico approaches to off-target profiling.\u003c\/p\u003e \u003cp\u003e2.5 Summary and conclusions.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Pharmacological promiscuity and molecular properties\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJens-Uwe Peters\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction: pharmacological promiscuity in the history of drug discovery.\u003c\/p\u003e \u003cp\u003e3.2 Lipophilicity.\u003c\/p\u003e \u003cp\u003e3.3 Molecular weight.\u003c\/p\u003e \u003cp\u003e3.4 Ionisation state.\u003c\/p\u003e \u003cp\u003e3.5 Other molecular descriptors and structural motifs.\u003c\/p\u003e \u003cp\u003e3.6 Implications for drug discovery.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Kinases as antitargets in genotoxicity\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eStephan Kirchner\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Protein Kinases and inhibitor-binding sites.\u003c\/p\u003e \u003cp\u003e4.2 Cyclin-Dependent Kinases (CDKs) controlling unregulated cell proliferation.\u003c\/p\u003e \u003cp\u003e4.3 Mitotic kinases as guardians protecting cells from aberrant chromosome segregation.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Activity at cardiovascular ion channels: a key issue for drug discovery\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eIan M. Bell, Mark T. Bilodeau and Armando A. Lagrutta\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction.\u003c\/p\u003e \u003cp\u003e5.2 Screening methods.\u003c\/p\u003e \u003cp\u003e5.3 Structural insights into the interaction between drugs and CV ion channels.\u003c\/p\u003e \u003cp\u003e5.4 Medicinal Chemistry approaches.\u003c\/p\u003e \u003cp\u003e5.5 Conclusion.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Prediction of side effects based on fingerprint profiling and data mining\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJacques Migeon\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction to BioPrint.\u003c\/p\u003e \u003cp\u003e6.2 The pharmacological fingerprint.\u003c\/p\u003e \u003cp\u003e6.3 Antidepressant example.\u003c\/p\u003e \u003cp\u003e6.4 Profile similarity at non-therapeutic targets.\u003c\/p\u003e \u003cp\u003e6.5 Interpreting the polypharmacology profile.\u003c\/p\u003e \u003cp\u003e6.6 Methods.\u003c\/p\u003e \u003cp\u003e6.7 Patterns of activity.\u003c\/p\u003e \u003cp\u003e6.8 Integrating function profile data with traditional pharmacological binding data.\u003c\/p\u003e \u003cp\u003e6.9 Analysis of the antifungal tioconazole.\u003c\/p\u003e \u003cp\u003e6.10 Conclusions.\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart B: Polypharmacology – an opportunity for drug discovery.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Polypharmacological drugs – \"magic shotguns\" for psychiatric diseases\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eWesley K. Kroeze and Bryan L. Roth\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction.\u003c\/p\u003e \u003cp\u003e7.2 Definition.\u003c\/p\u003e \u003cp\u003e7.3 The discovery and extent of promiscuity among psychiatric drugs.\u003c\/p\u003e \u003cp\u003e7.4 Why are so many psychiatric drugs promiscuous?\u003c\/p\u003e \u003cp\u003e7.5 Conclusions.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Polypharmacological kinase inhibitors: new hopes for the therapy of cancer\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAnnalisa Petrelli\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Targeted therapies: a new era in the treatment of cancer.\u003c\/p\u003e \u003cp\u003e8.2 The single-targeted therapy.\u003c\/p\u003e \u003cp\u003e8.3 From single to multi-targeted drugs in cancer therapy.\u003c\/p\u003e \u003cp\u003e8.4 Polypharmacology kinase inhibitors in clinical practice and under development.\u003c\/p\u003e \u003cp\u003e8.5 Concluding remarks.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Polypharmacology as an emerging trend in antibacterial discovery\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eLynn L. Silver\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction.\u003c\/p\u003e \u003cp\u003e9.2 Classical antibacterial polypharmacology.\u003c\/p\u003e \u003cp\u003e9.3 New approaches to multi-targeted single pharmacophores.\u003c\/p\u003e \u003cp\u003e9.4 Synthetic lethals.\u003c\/p\u003e \u003cp\u003e9.5 Hybrid molecules.\u003c\/p\u003e \u003cp\u003e9.6 Conclusions.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 A \"magic shotgun\" perspective on anticonvulsant mechanisms\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMatt T. Bianchi and Kathy Chuang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction.\u003c\/p\u003e \u003cp\u003e10.2 Anticonvulsant mechanism.\u003c\/p\u003e \u003cp\u003e10.3 Defining promiscuity.\u003c\/p\u003e \u003cp\u003e10.4 Promiscuity: lessons from endogenous signaling.\u003c\/p\u003e \u003cp\u003e10.5 Promiscuity: lessons from anticonvulsant electrophysiology.\u003c\/p\u003e \u003cp\u003e10.6 Use of anticonvulsants in disorders other than epilepsy.\u003c\/p\u003e \u003cp\u003e10.7 Experimental and theoretical support for a \"Magic Shotgun\" approach.\u003c\/p\u003e \u003cp\u003e10.8 Current multi-target strategies.\u003c\/p\u003e \u003cp\u003e10.9 Practical considerations.\u003c\/p\u003e \u003cp\u003e10.10 Conclusion.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Selective Optimization of Side Activities (SOSA): a promising way for drug discovery\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eThierry Langer and Camille-Georges Wermuth\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction.\u003c\/p\u003e \u003cp\u003e11.2 Definition and principle.\u003c\/p\u003e \u003cp\u003e11.3 Rationale of SOSA.\u003c\/p\u003e \u003cp\u003e11.4 Establishing the SOSA approach.\u003c\/p\u003e \u003cp\u003e11.5 A successful example of the SOSA approach.\u003c\/p\u003e \u003cp\u003e11.6 Other examples of SOSA switches.\u003c\/p\u003e \u003cp\u003e11.7 Discussion.\u003c\/p\u003e \u003cp\u003e11.8 Computer-assisted design using pharmacophores.\u003c\/p\u003e \u003cp\u003e11.9 Conclusions.\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart C: Selected approaches to polypharmacological drug discovery\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12\u003c\/b\u003e \u003cb\u003eSelective multi-targeted drugs\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eRichard Morphy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction.\u003c\/p\u003e \u003cp\u003e12.2 Lead Generation.\u003c\/p\u003e \u003cp\u003e12.3 Lead optimization.\u003c\/p\u003e \u003cp\u003e12.4 Case studies.\u003c\/p\u003e \u003cp\u003e12.5 Summary.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Computational multitarget drug discovery\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJeremy A. Horst, Adrian Laurenzi, Brady Bernard and Ram Samudrala\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction.\u003c\/p\u003e \u003cp\u003e13.2 The pharmacologic hunt of yesteryear.\u003c\/p\u003e \u003cp\u003e13.3.Established technological advancements.\u003c\/p\u003e \u003cp\u003e13.4.Computational drug discovery.\u003c\/p\u003e \u003cp\u003e13.5.Recent technical improvements.\u003c\/p\u003e \u003cp\u003e13.6.Emerging concepts.\u003c\/p\u003e \u003cp\u003e13.7 Summary.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Behavior-based screening as an approach to polypharmacological ligands\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eDani Brunner, Vadim Alexandrov, Barbara Caldarone, Taleen Hanania, David Lowe, Jeff Schneider and Jayaraman Chandrasekhar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 The Challenges of CNS Drug Discovery.\u003c\/p\u003e \u003cp\u003e14.2 In vivo high throughput screening.\u003c\/p\u003e \u003cp\u003e14.3 Screening libraries of compounds.\u003c\/p\u003e \u003cp\u003e14.4 Relationship between molecular properties and in vivo CNS activity.\u003c\/p\u003e \u003cp\u003e14.5 Following screening hits in secondary assays.\u003c\/p\u003e \u003cp\u003e14.6 Potential therapeutic value of dual adenosine compounds.\u003c\/p\u003e \u003cp\u003e14.7 Summary.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15\u003c\/b\u003e \u003cb\u003eMulticomponent Therapeutics\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAlexis A. Borisy, Grant R. Zimmermann and Joseph Lehár\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 Introduction.\u003c\/p\u003e \u003cp\u003e15.2 Drug synergies are statistically more context dependent.\u003c\/p\u003e \u003cp\u003e15.3 How a synergistic mechanism can lead to therapeutic selectivity.\u003c\/p\u003e \u003cp\u003e15.4 Discussion.\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart D: Case studies\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 The discovery of sunitinib as a multitarget treatment of cancer\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eCatherine Delbaldo, Camelia Colichi, Marie-Paule Sablin, Chantal Dreyer, Bertrand Billemont, Sandrine Faivre and Eric Raymond\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 A brief introduction to tumor angiogenesis.\u003c\/p\u003e \u003cp\u003e16.2 The discovery of sunitinib: from drug design to first evidences of clinical activity.\u003c\/p\u003e \u003cp\u003e16.3 Pharmacology of sunitinib.\u003c\/p\u003e \u003cp\u003e16.4 Safety of sunitinib.\u003c\/p\u003e \u003cp\u003e16.5 Activity of Sunitinib.\u003c\/p\u003e \u003cp\u003e16.6 Surrogate imaging techniques to capture vascular changes.\u003c\/p\u003e \u003cp\u003e16.7 Surrogate biomarkers.\u003c\/p\u003e \u003cp\u003e16.8 Conclusion.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17\u003c\/b\u003e \u003cb\u003eAntipsychotics\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eClaus Riemer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17.1 Definition and diagnosis of schizophrenia.\u003c\/p\u003e \u003cp\u003e17.2 Etiology and pathophysiology of schizophrenia.\u003c\/p\u003e \u003cp\u003e17.3 Epidemiology.\u003c\/p\u003e \u003cp\u003e17.4 Medical practice and treatment options.\u003c\/p\u003e \u003cp\u003e17.5 Case studies.\u003c\/p\u003e \u003cp\u003e17.6 CATIE.\u003c\/p\u003e \u003cp\u003e17.7 Conclusions.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Triple Uptake Inhibitors (\"Broad Spectrum\" Antidepressants)\u003cbr\u003e \u003c\/b\u003e\u003ci\u003ePhil Skolnick\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18.1 Introduction.\u003c\/p\u003e \u003cp\u003e18.2 What is the rationale for developing triple uptake inhibitors as antidepressants?\u003c\/p\u003e \u003cp\u003e18.3 Preclinical data.\u003c\/p\u003e \u003cp\u003e18.4 Clinical data.\u003c\/p\u003e \u003cp\u003e18.5 Concluding remarks.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Therapeutic potential of small molecules modulating the cyclooxygenase and 5-lipoxygenase pathway\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eStefan Laufer and Wolfgang Albrecht\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19.1 Targets of the eicosanoid pathway.\u003c\/p\u003e \u003cp\u003e19.2 Rationale for development of dual inhibitors of the cyclooxygenase and 5-lipoxygenase pathway.\u003c\/p\u003e \u003cp\u003e19.3 Dual inhibitors of the cyclooxygenase and 5-lipoxygenase pathway.\u003c\/p\u003e \u003cp\u003e19.4 Development of Licofelone.\u003c\/p\u003e \u003cp\u003e19.5 Conclusions.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e20\u003c\/b\u003e \u003cb\u003eDrug research leading to imatinib and beyond to nilotinib\u003cbr\u003e \u003c\/b\u003e\u003ci\u003ePaul W. Manley and Jürg Zimmermann\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20.1 Introduction.\u003c\/p\u003e \u003cp\u003e20.2 Historical background.\u003c\/p\u003e \u003cp\u003e20.3 BCR-ABL1 as the molecular target for CML therapy.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e21 Towards antimalarial hybrid drugs\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eBernard Meunier\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e22 Multitarget drugs for the treatment of Alzheimer’s disease\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAndrea Cavalli and Maria Laura Bolognesi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22.1 Introduction.\u003c\/p\u003e \u003cp\u003e22.2 Case studies.\u003c\/p\u003e \u003cp\u003e22.3 Conclusions and perspectives.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e23 Carbonic anhydrases: off-targets, add-on activities, or emerging novel targets?\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eClaudiu Supuran\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23.1 Introduction.\u003c\/p\u003e \u003cp\u003e23.2 Carbonic anhydrase inhibition.\u003c\/p\u003e \u003cp\u003e23.3 Topiramate and zonisamide, antiepileptics with potent antiobesity action.\u003c\/p\u003e \u003cp\u003e23.4 Sulfonamide coxibs with antitumor activity due to CA IX\/XII inhibition.\u003c\/p\u003e \u003cp\u003e23.5 Sulfamates with steroid sulfatase and carbonic anhydrase inhibitory action as anticancer agents in clinical development.\u003c\/p\u003e \u003cp\u003e23.6 Lacosamide, an antiepileptic with a strange binding mode to Cas.\u003c\/p\u003e \u003cp\u003e23.7 The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian CA isoforms.\u003c\/p\u003e \u003cp\u003e23.8 Conclusions.\u003c\/p\u003e  \u003cp\u003e“The book is well presented and the price is reasonable for anyone (drug designers, medicinal chemists, biochemists, biologists, clinicians and toxicologists) interested in any of the many facets that come together to make polypharmacology.”  (\u003ci\u003eBritish Toxicology Society\u003c\/i\u003e, 1 July 2013)\u003c\/p\u003e \u003cp\u003e“However, anyone interested in the complex issues relating to drug promiscuity should find this very timely and topical book to be a reliable and stimulating reference that they will revisit many times.”  (\u003ci\u003eChemMedChem\u003c\/i\u003e, 2012)\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e  \u003cp\u003eJens-Uwe Peters, PhD, works in the Medicinal Chemistry Department at F. Hoffmann-La Roche. In his ten years at Roche, he has been involved in numerous drug discovery projects, has contributed to Early Safety Profiling initiatives, and has researched opportunities for polypharmacological drug discovery. Dr. Peters is author or coauthor on twenty-six journal papers and is named on twenty-two patents.\u003c\/p\u003e  \u003cp\u003eAn essential outline of the main facets of polypharmacology in drug discovery research\u003c\/p\u003e \u003cp\u003eExtending drug discovery opportunities beyond the \"one drug, one target\" philosophy, a polypharmacological approach to the treatment of complex diseases is emerging as a hot topic in both industry and academic research. Polypharmacology in Drug Discovery presents an overview of the various facets of polypharmacology and how it can be applied as an innovative concept for developing medicines for treating bacterial infections, epilepsy, cancer, psychiatric disorders, and more. Filled with a collection of instructive case studies that reinforce the material and illuminate the subject, this practical guide:\u003c\/p\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003eCovers the two-sided nature of polypharmacology—its contribution to adverse drug reactions and its benefit in certain therapeutic drug classes\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eAddresses the important topic of polypharmacology in drug discovery, a subject that has not been thoroughly covered outside of scattered journal articles\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eOverviews state-of-the-art approaches and developments to help readers understand concepts and issues related to polypharmacology\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eFosters interdisciplinary drug discovery research by embracing computational, synthetic, in vitro and in vivo pharmacological and clinical aspects of polypharmacology\u003c\/p\u003e \u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eA clear road map for helping readers successfully navigate around the problems involved with promiscuous ligands and targets, Polypharmacology in Drug Discovery provides real examples, in-depth explanations and discussions, and detailed reviews and opinions to spark inspiration for new drug discovery projects.\u003c\/p\u003e  \u003cp\u003e“Only recently, the characterization of promiscuous ligands turned from ‘dirty drugs’ into ‘agents being rich in pharmacology.’ … \u003ci\u003ePolypharmacology in Drug Discovery\u003c\/i\u003e covers all aspects, the good, the bad and the ugly. On the one hand, a lack of specificity (the ‘bad’) causes more or less serious side effects; inhibition of certain antitargets (the ‘ugly’), e.g. the hERG channel, results in a termination of a development project, in the past even the withdrawal of already marketed drugs; on the other hand, a desired promiscuity (the ‘good’) may be beneficial, e.g. in the case of certain CNS drugs and of anti-tumor kinase inhibitors. In Peters‘ book, all these topics are discussed in great detail by internationally leading authors. Therefore, \u003ci\u003ePolypharmacology in Drug Discovery\u003c\/i\u003e is of utmost importance for all drug designers, medicinal chemists as well as biochemists and biologists. The price of the book is in excellent relationship to its 500 pages and the overall quality, in content and presentation.”—Prof. Dr. Hugo Kubinyi\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47989813346533,"sku":"NP9780470590904","price":153.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470590904.jpg?v=1761785554","url":"https:\/\/k12savings.com\/es\/products\/polypharmacology-in-drug-discovery-isbn-9780470590904","provider":"K12savings","version":"1.0","type":"link"}